Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients.
OBJECTIVE
Previous studies have been inconsistent results about the effects of statins on serum triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and high sensitivity C-reactive protein (hsCRP) levels. We therefore investigated the effects of pitavastatin on serum lipid profiles and hsCRP levels in patients with type 2 diabetes mellitus.


METHODS
The study population was 65 Japanese type 2 diabetic patients who had been administered 2 mg daily of pitavastatin and completed a 6-month follow-up. Serum lipids and hsCRP were measured before and after treatment for 1, 3, and 6 months.


RESULTS
Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and TG had significantly reduced after 1 month and remained reduced for 6 months, while HDL-C levels had significantly increased after 1 month and remained at the higher level for 6 months. Baseline median levels of hsCRP were 0.49 mg/L and showed a significant reduction to 0.37 mg/L at 6 months' treatment (p<0.001). Six-month changes in hsCRP levels were not associated with those in TC, LDL-C, HDL-C or TG.


CONCLUSIONS
Pitavastatin improved serum lipid profiles and reduced serum hsCRP levels in type 2 diabetic patients with relatively low inflammation. The effect on hsCRP was not related to the effects on serum lipid profiles.
Motomura
Takashi
T
Department of Medicine, NTT West Osaka Hospital, Japan.
Okamoto
Maki
M
Kitamura
Tetsuhiro
T
Yamamoto
Hiroyasu
H
Otsuki
Michio
M
Asanuma
Nobuyuki
N
Takagi
Miki
M
Kurebayashi
Shogo
S
Hashimoto
Kunihiko
K
Sumitani
Satoru
S
Saito
Hiroshi
H
Kouhara
Haruhiko
H
Nshii
Kazumasa
K
Nakao
Makoto
M
Koga
Masafumi
M
Sato
Bunzo
B
Morimoto
Yasuhiko
Y
Kasayama
Soji
S
D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011804:Quinolines / Q000627:therapeutic use*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011804:Quinolines; D002097:C-Reactive Protein; C108475:pitavastatin